A photoresist composition containing (A) a polymer having a structural unit (I) that includes an acid-labile group, and (I) a compound represented by the following formula (1). In the following formula (1), R.sup.1, R.sup.2, R.sup.3 and R represent a hydrogen atom or a monovalent organic group having 1 to 20 carbon atoms. X represents a single bond, an oxygen atom or —NR.sup.a—. R.sup.a represents a hydrogen atom, a hydroxy group or a monovalent organic group having 1 to 20 carbon atoms, and optionally taken together represents a ring structure by binding with R each other. A.sup.− represents —SO.sub.3.sup.− or —CO.sub.2.sup.−. M.sup.+ represents a monovalent onium cation. ##STR00001##

A photoresist composition containing (A) a polymer having a structural unit (I) that includes an acid-labile group, and (I) a compound represented by the following formula (1). In the following formula (1), R.sup.1, R.sup.2, R.sup.3 and R represent a hydrogen atom or a monovalent organic group having 1 to 20 carbon atoms. X represents a single bond, an oxygen atom or —NR.sup.a—. R.sup.a represents a hydrogen atom, a hydroxy group or a monovalent organic group having 1 to 20 carbon atoms, and optionally taken together represents a ring structure by binding with R each other. A.sup.− represents —SO.sub.3.sup.− or —CO.sub.2.sup.−. M.sup.+ represents a monovalent onium cation. ##STR00001##

Disclosed herein is a method of making a 2-(2,3-epoxypropyl)phenol by reacting a 2-allylphenol with an oxidant in the presence of a catalyst. A 3-chromanol can be formed as a by-product. The method can be used to make 2-(2,3-epoxypropyl)-6-methylphenol. Transition metal catalysts and peroxide oxidants can be used. Also disclosed is a composition comprising 1 to 90 weight percent of a 2-(2,3-epoxypropylphenol, 5 to 90 weight percent of a 2-allylphenol, and 0 to 40 weight percent of a 3-chromanol, and in particular, a composition comprising 1 to 90 weight percent 2-(2,3-epoxypropyl)-6-methylphenol, 5 to 90 weight percent 2-allyl-6-methylphenol, and 0 to 40 weight percent 8-methyl-3-chromanol.

Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.

Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.

The present invention relates to a compound of the following general formula (I); or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation. ##STR00001##

The present invention relates to a compound of the following general formula (I); or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation. ##STR00001##

The present document describes apple peel polyphenolic extract comprising a proanthocyanidin content of at least 15000 μg/g of dry weight, comprising about 30% to about 35% epicatechin content, and pharmaceutical composition comprising the apple peel polyphenolic extract. The present document also describes methods and use of the apple peel polyphenolic extract for preventing or treating conditions such as oxidative stress, inflammation and mitochondrial dysfunction of the liver, insulin resistance, intestinal endothelial tissue injury, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis (NASH), liver fibrosis, liver cirrhosis, and/or inhibition of de novo lipogenesis and β-oxidation of free fatty acids for preventing accumulation thereof in the liver. The present document also describes a process for extraction of at least a polyphenol content from dry apple peel powder.

Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.

Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.